BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 19366569)

  • 1. Development of a live-attenuated influenza B DeltaNS1 intranasal vaccine candidate.
    Wressnigg N; Voss D; Wolff T; Romanova J; Ruthsatz T; Mayerhofer I; Reiter M; Nakowitsch S; Humer J; Morokutti A; Muster T; Egorov A; Kittel C
    Vaccine; 2009 May; 27(21):2851-7. PubMed ID: 19366569
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influenza A and B viruses expressing altered NS1 proteins: A vaccine approach.
    Talon J; Salvatore M; O'Neill RE; Nakaya Y; Zheng H; Muster T; García-Sastre A; Palese P
    Proc Natl Acad Sci U S A; 2000 Apr; 97(8):4309-14. PubMed ID: 10725408
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protection afforded by intranasal immunization with the neuraminidase-lacking mutant of influenza A virus in a ferret model.
    Mishin VP; Nedyalkova MS; Hayden FG; Gubareva LV
    Vaccine; 2005 Apr; 23(22):2922-7. PubMed ID: 15780741
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Strong local and systemic protective immunity induced in the ferret model by an intranasal virosome-formulated influenza subunit vaccine.
    Lambkin R; Oxford JS; Bossuyt S; Mann A; Metcalfe IC; Herzog C; Viret JF; Glück R
    Vaccine; 2004 Oct; 22(31-32):4390-6. PubMed ID: 15474733
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical evaluation of a replication-deficient intranasal DeltaNS1 H5N1 influenza vaccine.
    Romanova J; Krenn BM; Wolschek M; Ferko B; Romanovskaja-Romanko E; Morokutti A; Shurygina AP; Nakowitsch S; Ruthsatz T; Kiefmann B; König U; Bergmann M; Sachet M; Balasingam S; Mann A; Oxford J; Slais M; Kiselev O; Muster T; Egorov A
    PLoS One; 2009 Jun; 4(6):e5984. PubMed ID: 19543385
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development and characterization of a live attenuated influenza B virus vaccine candidate.
    Seo SU; Byun YH; Lee EY; Jung EJ; Jang YH; Kim HA; Ha SH; Lee KH; Seong BL
    Vaccine; 2008 Feb; 26(7):874-81. PubMed ID: 18207290
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of live attenuated influenza vaccine in children against influenza B viruses by lineage and antigenic similarity.
    Belshe RB; Coelingh K; Ambrose CS; Woo JC; Wu X
    Vaccine; 2010 Feb; 28(9):2149-56. PubMed ID: 20003926
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutations affecting the stability of the haemagglutinin molecule impair the immunogenicity of live attenuated H3N2 intranasal influenza vaccine candidates lacking NS1.
    Nakowitsch S; Wolschek M; Morokutti A; Ruthsatz T; Krenn BM; Ferko B; Ferstl N; Triendl A; Muster T; Egorov A; Romanova J
    Vaccine; 2011 Apr; 29(19):3517-24. PubMed ID: 21406268
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I/II trial of a replication-deficient trivalent influenza virus vaccine lacking NS1.
    Mössler C; Groiss F; Wolzt M; Wolschek M; Seipelt J; Muster T
    Vaccine; 2013 Dec; 31(52):6194-200. PubMed ID: 24183981
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Rescued influenza A virus with codon deoptimized NS1 gene is attenuated both in vitro and in vivo].
    Luan S; Pan W; Li T; Yang H; Zhang B; Li F; Chen L
    Sheng Wu Gong Cheng Xue Bao; 2009 May; 25(5):720-6. PubMed ID: 19670641
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel type of influenza vaccine: safety and immunogenicity of replication-deficient influenza virus created by deletion of the interferon antagonist NS1.
    Wacheck V; Egorov A; Groiss F; Pfeiffer A; Fuereder T; Hoeflmayer D; Kundi M; Popow-Kraupp T; Redlberger-Fritz M; Mueller CA; Cinatl J; Michaelis M; Geiler J; Bergmann M; Romanova J; Roethl E; Morokutti A; Wolschek M; Ferko B; Seipelt J; Dick-Gudenus R; Muster T
    J Infect Dis; 2010 Feb; 201(3):354-62. PubMed ID: 20039806
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Generation of DelNS1 Influenza Viruses: a Strategy for Optimizing Live Attenuated Influenza Vaccines.
    Wang P; Zheng M; Lau SY; Chen P; Mok BW; Liu S; Liu H; Huang X; Cremin CJ; Song W; Chen Y; Wong YC; Huang H; To KK; Chen Z; Xia N; Yuen KY; Chen H
    mBio; 2019 Sep; 10(5):. PubMed ID: 31530680
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of live influenza vaccine donor strain derived from cold-adaptation of X-31 virus.
    Lee KH; Seo SU; Song JM; Lee CM; Kim HA; Seong BL
    Vaccine; 2006 Mar; 24(11):1966-74. PubMed ID: 16343703
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of live attenuated vaccines against 2009 pandemic H1N1 influenza in ferrets.
    Stittelaar KJ; Veldhuis Kroeze EJ; Rudenko L; Dhere R; Thirapakpoomanunt S; Kieny MP; Osterhaus AD
    Vaccine; 2011 Nov; 29(49):9265-70. PubMed ID: 21945964
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MDCK cell line with inducible allele B NS1 expression propagates delNS1 influenza virus to high titres.
    van Wielink R; Harmsen MM; Martens DE; Peeters BP; Wijffels RH; Moormann RJ
    Vaccine; 2011 Sep; 29(40):6976-85. PubMed ID: 21787829
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Preclinical studies of live intranasal H5N1 influenza vaccine with the deleted HS1 gene].
    Romanovskaia-Roman'ko EA; Ferko B; Vyshemirskiĭ OI; Romanova IuR; Krenn B; Muster T; Grudinin MP; Lapin BA; Egorov AIu; Kiselev OI
    Vopr Virusol; 2011; 56(6):19-22. PubMed ID: 22359944
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The potential of a protease activation mutant of a highly pathogenic avian influenza virus for a pandemic live vaccine.
    Gabriel G; Garn H; Wegmann M; Renz H; Herwig A; Klenk HD; Stech J
    Vaccine; 2008 Feb; 26(7):956-65. PubMed ID: 18164519
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Live cold-adapted influenza A vaccine produced in Vero cell line.
    Romanova J; Katinger D; Ferko B; Vcelar B; Sereinig S; Kuznetsov O; Stukova M; Erofeeva M; Kiselev O; Katinger H; Egorov A
    Virus Res; 2004 Jul; 103(1-2):187-93. PubMed ID: 15163508
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Shedding and immunogenicity of live attenuated influenza vaccine virus in subjects 5-49 years of age.
    Block SL; Yogev R; Hayden FG; Ambrose CS; Zeng W; Walker RE
    Vaccine; 2008 Sep; 26(38):4940-6. PubMed ID: 18662737
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rearrangement of Influenza Virus Spliced Segments for the Development of Live-Attenuated Vaccines.
    Nogales A; DeDiego ML; Topham DJ; Martínez-Sobrido L
    J Virol; 2016 Jul; 90(14):6291-6302. PubMed ID: 27122587
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.